Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency
Antoine Simoneau(Io Therapeutics (United States)), Scott Throner(Tango Therapeutics (United States))
Cited by 17
Related Papers
Identification of Somatically Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer
|Clinical Cancer Research|2020|24